stockrowCytokinetics, Incorporated
CYTK Healthcare Biotechnology
Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.
- Revenue
- +2,356.5%
- EPS
- +46.3%
- Free cash flow
- −6.73%
- Total debt
- −83.9%
Quarter to September 2026, against a year earlier
Follow CYTK
Alert me
Cytokinetics, Incorporated (CYTK) Net income
Cytokinetics, Incorporated's net income for fiscal 2025 was −$785.0M, compared with −$589.5M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$777.9M. Over the past ten years it has ranged from −$785.0M (fiscal 2025) to $16.5M (fiscal 2016) — the current reading is the lowest in ten years. Net income has fallen for 7 consecutive fiscal years. Cytokinetics, Incorporated ranks 598th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$785.0M | — |
| FY2024 | −$589.5M | — |
| FY2023 | −$526.2M | — |
| FY2022 | −$389.0M | — |
| FY2021 | −$215.3M | — |
| FY2020 | −$127.3M | — |
| FY2019 | −$121.7M | — |
| FY2018 | −$106.3M | — |
| FY2017 | −$127.8M | — |
| FY2016 | $16.5M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$190.1M | — |
| Jun 2026 | −$198.8M | — |
| Mar 2026 | −$206.0M | — |
| Dec 2025 | −$183.0M | — |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $225.2M |
| CORT Corcept Therapeutics Incorporated compare | $162.3M |
| CAI Caris Life Sciences,�Inc. compare | $96.1M |
| PTGX Protagonist Therapeutics, Inc. compare | $82.9M |
| TWST Twist Bioscience Corporation compare | −$136.7M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$155.5M |
| SYRE Spyre Therapeutics, Inc. compare | −$263.9M |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −$272.1M |
| CYTK Cytokinetics, Incorporated | −$777.9M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on CYTK
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement